Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation Research
Search: search_blue_button Advanced Search
Circulation Research. 2006;98:105-110
Published online before print November 23, 2005, doi: 10.1161/01.RES.0000197851.11031.9c
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
98/1/105    most recent
01.RES.0000197851.11031.9cv1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Moosmang, S.
Right arrow Articles by Hofmann, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Moosmang, S.
Right arrow Articles by Hofmann, F.
Related Collections
Right arrow Animal models of human disease
Right arrow Other hypertension
Right arrow Genetically altered mice
Right arrow Hypertension - basic studies
Right arrow Ion channels/membrane transport
Right arrow Genetics of cardiovascular disease
Right arrow Other Vascular biology
(Circulation Research. 2006;98:105.)
© 2006 American Heart Association, Inc.


Cellular Biology

Antihypertensive Effects of the Putative T-Type Calcium Channel Antagonist Mibefradil Are Mediated by the L-Type Calcium Channel Cav1.2

Sven Moosmang, Nicole Haider, Birgit Brüderl, Andrea Welling, Franz Hofmann

From the Institut für Pharmakologie und Toxikologie, Technische Universität München, Germany.

Correspondence to Dr Sven Moosmang, Institut für Pharmakologie und Toxikologie der Technischen Universität München, Biedersteiner Strasse 29, 80802 München, Germany. E-mail moosmang{at}ipt.med.tu-muenchen.de

The role of T-type Ca2+ channels for cardiovascular physiology, in particular blood pressure regulation, is controversial. Selective blockade of T-type Ca2+ channels in resistance arteries has been proposed to explain the effect of the antihypertensive drug mibefradil. In the present study, we used a third generation, time- and tissue-specific conditional knockout model of the L-type Ca2+ channel Cav1.2 (Cav1.2SMAKO mice) to genetically dissect the effects of mibefradil on T- and L-type Ca2+ channels. Myogenic tone and phenylephrine-induced contraction in hindlimb perfusion experiments were sensitive to mibefradil in control mice, whereas the drug showed no effect in Cav1.2-deficient animals. Mean arterial blood pressure in awake, freely moving control mice was reduced by 38±2.5 mm Hg at a dose of 1.25 mg/kg bodyweight mibefradil, but not changed in Cav1.2SMAKO mice. These results demonstrate that the effect of the putative T-type Ca2+ channel-selective blocker mibefradil on blood pressure and small vessel myogenic tone is mediated by the Cav1.2 L-type Ca2+ channel.


Key Words: calcium channel • T-type • L-type • mibefradil • blood pressure




This article has been cited by other articles:


Home page
HypertensionHome page
C. J. Ball, D. P. Wilson, S. P. Turner, D. A. Saint, and J. F. Beltrame
Heterogeneity of L- and T-Channels in the Vasculature: Rationale for the Efficacy of Combined L- and T-Blockade
Hypertension, April 1, 2009; 53(4): 654 - 660.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
E. Perez-Reyes, A. L. Van Deusen, and I. Vitko
Molecular Pharmacology of Human Cav3.2 T-Type Ca2+ Channels: Block by Antihypertensives, Antiarrhythmics, and Their Analogs
J. Pharmacol. Exp. Ther., February 1, 2009; 328(2): 621 - 627.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
R. Schubert, D. Lidington, and S.-S. Bolz
The emerging role of Ca2+ sensitivity regulation in promoting myogenic vasoconstriction
Cardiovasc Res, January 1, 2008; 77(1): 8 - 18.
[Abstract] [Full Text] [PDF]


Home page
FASEB J.Home page
K. R. Watterson, K. M. Berg, D. Kapitonov, S. G. Payne, A. S. Miner, R. Bittman, S. Milstien, P. H. Ratz, and S. Spiegel
Sphingosine-1-phosphate and the immunosuppressant, FTY720-phosphate, regulate detrusor muscle tone
FASEB J, September 1, 2007; 21(11): 2818 - 2828.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
X. F. Figueroa, C.-C. Chen, K. P. Campbell, D. N. Damon, K. H. Day, S. Ramos, and B. R. Duling
Are voltage-dependent ion channels involved in the endothelial cell control of vasomotor tone?
Am J Physiol Heart Circ Physiol, September 1, 2007; 293(3): H1371 - H1383.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
L. Lipskaia, C. Pinet, Y. Fromes, S. Hatem, I. Cantaloube, A. Coulombe, and A.-M. Lompre
Mutation of {delta}-Sarcoglycan Is Associated with Ca2+-Dependent Vascular Remodeling in the Syrian Hamster
Am. J. Pathol., July 1, 2007; 171(1): 162 - 171.
[Abstract] [Full Text] [PDF]


Home page
J. Physiol.Home page
A. M. Blanks, Z.-H. Zhao, A. Shmygol, G. Bru-Mercier, S. Astle, and S. Thornton
Characterization of the molecular and electrophysiological properties of the T-type calcium channel in human myometrium
J. Physiol., June 15, 2007; 581(3): 915 - 926.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
K. Hayashi, S. Wakino, N. Sugano, Y. Ozawa, K. Homma, and T. Saruta
Ca2+ Channel Subtypes and Pharmacology in the Kidney
Circ. Res., February 16, 2007; 100(3): 342 - 353.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
B. S. Freeze, M. M. McNulty, and D. A. Hanck
State-Dependent Verapamil Block of the Cloned Human Cav3.1 T-Type Ca2+ Channel
Mol. Pharmacol., August 1, 2006; 70(2): 718 - 726.
[Abstract] [Full Text] [PDF]